复星医药左氧氟沙星注射剂新药注册申请获中国药监局批准

美股速递
May 21

上海复星医药(集团)股份有限公司宣布,其提交的左氧氟沙星注射剂新药注册申请,已获得中国国家药品监督管理局的正式批准。这一进展标志着该产品在中国市场上市销售的关键监管障碍已被清除。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10